Notice to noteholders regarding change of control

Following the public tender offer to the shareholders of Meda AB (publ) (the “Issuer”) as of 10 February, 2016, Mylan N.V. (“Mylan”) has as per 5 August 2016 confirmed it has become owner of approximately 94 per cent of the shares and votes in the Issuer. The acquisition of the shares in the Issuer by Mylan constitutes a change of control event as further described in the terms and conditions for each of the 2013/2018 SEK 600,000,000 Floating Rate Notes (ISIN: SE0005132180) and 2014/2019 SEK 750,000,000 Floating Rate Notes (ISIN: SE0005991635) issued by the Issuer (collectively the “Notes”).

As a result of the change of control event, each noteholder may exercise its right to redemption of its Notes, in whole or in parts, at a price equal to 100 percent of the nominal amount (SEK 1,000,000 per MTN) together with accrued but unpaid interest up until and including the Repurchase Date (as defined below and in Sw.: Lösendagen), pursuant to condition 8 (Early Redemption (Sw.: Förtida Inlösen)) of the terms and conditions. A noteholder who wants to exercise its right to redemption of its Notes, in whole or in parts, shall sign and send a repurchase instruction form to the following e-mail address:

Skandinaviska Enskilda Banken AB (publ) E-mail:

The repurchase instruction is separately provided to noteholders by the Issuer via Euroclear Sweden’s messaging service or can be obtained from Skandinaviska Enskilda Banken AB (publ) (“SEB”) (see contact details above). The repurchase instruction requires disclosure of the ultimate beneficial ownership information to SEB. Please note that a complete repurchase instruction form must have been received by SEB no later than 4 October, 2016 in order to be valid. A submitted repurchase instruction form may be revoked before that time and date.

The repurchase date applicable to those noteholders who has sent a repurchase instruction form in respect of all, or some only, of their Notes due to the change of control event, in due time will be 3 November, 2016 (the “Repurchase Date”).

For further inquiries, please contact:

Paula Treutiger, VP Corporate Communications & Sustainability                                     ph: +46 733-666 599                                                                                                                                                                                                        

This information is information that Meda AB is obliged to make public pursuant to the EU Market Abuse Regulation. The above information was submitted for publication, through the agency of the contact person set out above, 17:00 p.m. CET on 5 August 2016.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.